Able Opens a €750,000 Round to Achieve CE Marking

Able aims to enter the Spanish and German markets. To achieve this milestone, the company has opened a $786,600 (€750,000) financing round with the aim of financing the achievement of the CE marking of the European Union (EU), as explained Alfons Carnicero, co-founder and CEO of Able, to PlantaDoce. Part of the funds is already committed thanks to the participation of Banco Sabadell and a U.S. fund whose name has not been disclosed.

The Barcelona-based startup, which develops robotic exoskeletons for people with disabilities, has redone its initial plans after the pandemic and, after this bridge round, will open a Series A of up to $3.15 million (€3 million). Looking ahead to 2023, the company plans to start marketing its products in Germany and Spain.

In Germany, Carnicero highlights the fact that the company has carried out part of the clinical studies at the Heidelberg Hospital. In Spain, Able has also worked with the Guttman Institute in Badalona and the Asepeyo Barcelona Hospital in Sant Cugat, where the exoskeleton developed by Able is intended for patients with spinal cord injuries.

These people, without strength or sensitivity in their legs, put on the device, which is the one that makes the force after detecting the movements that the user wants to do.

Born2Invest application is a fast and easy way to check the latest business headlines. It gives users access to recent publications and stories, media and objective analysis, thematic sections and feeds. 

Able already closed a funding round of $734,500 (€700,000) in 2019

There are currently five million people with spinal cord injuries worldwide and this figure is increasing with half a million more people every year, according to Able’s calculations. Able promotes their mobility and aims to bring a holistic approach to the table, as spinal cord injuries lead to other associated health problems such as cardiovascular or psychological.

Able was founded in October 2018 on the initiative of Carnicero, Alex Garcia, and Josep Maria Font after research started in 2013 at the Universitat Politècnica de Catalunya (UPC) with the aim of developing a lightweight, easy-to-use device that would not be a great economic burden.

In November 2019, the company already closed a $734,500 (€700,000) funding round, in which the venture capital firm BStartup Health, Banco Sabadell’s program dedicated to healthcare startups, participated.

The company invested the funds raised in the transformation and evolution of the then prototype of the exoskeleton. Able is headquartered at the Centre de Recerca en Enginyeria Biomèdica in Barcelona and employs twelve full-time and two part-time employees.

__

(Featured image by Possessed Photography via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.